Context Therapeutics is trading at $0.24, down 7.75%, after Zacks added the stock to its Strong Sell list on October 15; the report does not explicitly attribute the intraday decline to the addition.
- Zacks cited a 15% downward revision to its current-year earnings consensus over the prior 60 days.
- Biotech was higher, while broad market indicators were mixed; these indicators do not clearly explain the drop.